PHI with BCG vaccination
How does this condition affect your private health insurance?
The BCG vaccination (Bacillus Calmette-Guérin) is an immunization against tuberculosis, primarily severe forms like childhood TB meningitis and disseminated TB. It uses a live, attenuated strain of Mycobacterium bovis. Administered intradermally, it typically causes a local reaction: a papule forming 2-4 weeks later, often progressing to a small ulcer, which eventually heals, leaving a characteristic scar over several months. While not a disease, it elicits an immune response. Side effects are generally mild, confined to the injection site, though regional lymphadenitis can occur. Severe complications are rare, mainly affecting immunocompromised individuals.
PKV Risk Assessment
Impact on Your Insurance Policy
Duration of Illness (Initial)
Local reaction lasts several weeks to months (papule, ulcer formation and healing).
Duration of Illness (Lifetime)
Protection against severe TB lasts approximately 10-15 years, not a continuous illness.
Cost of Treatment (Initial)
Cost of vaccine and administration varies, typically low, e.g., $10-$50 in many public health settings.
Cost of Treatment (Lifetime)
Generally negligible after initial vaccination, unless rare complications require treatment.
Mortality Rate
Extremely low, less than 1 in a million, primarily due to rare severe allergic reactions (anaphylaxis) or disseminated BCG infection in severely immunocompromised individuals.
Risk of Secondary Damages
Low. Common local reactions (scarring, lymphadenitis) occur in 1-10%. Severe complications like disseminated BCG infection are very rare, occurring in <1 per million doses, mainly in immunocompromised.
Probability of Full Recovery
Very high for local reactions; a scar typically remains. Recovery from severe complications depends on their nature and prompt treatment.
Underlying Disease Risk
Relevant underlying conditions that increase risk from the vaccine are primary immunodeficiency disorders, with a prevalence of approximately 1 in 10,000 to 1 in 50,000 live births, which must be screened for prior to vaccination.